Items that have been published by the UKCB are listed on this page
THE MANAGEMENT OF GLYCAEMIC CONTROL IN PATIENTS WITH CANCER - updated Sept 2021
Guidance for the diabetes and oncology multidisciplinary teams. Report of a working party on behalf of the UK Chemotherapy Board and Joint British Diabetes Societies for Inpatient Care.
CLINICIAN FAQS AND GUIDANCE ON COVID-19 VACCINE FOR PATIENTS RECEIVING SYSTEMIC ANTI-CANCER THERAPY (SACT). VERSION 5.0
Updated on website 24th Sept 2021
This document has been produced in response to questions raised by cancer health care professionals relating to the administration of the Pfizer/BioNTech COVID-19 vaccine and the Oxford University/AstraZeneca COVID-19 vaccine in patients receiving SACT.
PERSONALISED MEDICINE APPROACH FOR FLUOROPYRIMIDINE-BASED THERAPIES
To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
MEDICATION-RELATED OSTEONECROSIS OF THE JAW: GUIDANCE FOR THE ONCOLOGY MULTI-DISCIPLINARY TEAM
This guidance has been produced by a multi-disciplinary working party on behalf of the UK Chemotherapy Board and endorsed by the Clinical Standards Committee of the Faculty of Dental Surgery of the Royal College of Surgeons of England. It focuses on all aspects of medication-related osteonecrosis of the jaw (MRONJ) in relation to oncology patients.
UK Chemotherapy board endorsement policy to guide professional organisations requesting endorsement for documents, policies, position statements or meetings.
GOOD PRACTICE GUIDELINE FOR IMMUNO-ONCOLOGY MEDICINES
This guideline is designed to give a practical framework for the safe introduction and ongoing use of immunotherapy in existing Systemic Anti-Cancer Therapy (SACT) services.
PROMOTING EARLY IDENTIFICATION OF SYSTEMIC ANTI-CANCER THERAPIES SIDE EFFECTS: TWO APPROACHES – GOOD PRACTICE GUIDELINE
Guidance was produced in response to concerns that patients often delay reporting serious SACT side effects. Two complementary approaches to improve side effect reporting are suggested.
MORBIDITY AND MORTALITY WITHIN 30 DAYS OF SYSTEMIC ANTI-CANCER THERAPY - REVIEW OF CURRENT PRACTICE - STANDARDISED REVIEW PROCESS
The importance of having mortality meetings to review deaths within 30 days of treatment with SACT has been established and most trusts have developed their own system for deciding which cases to discuss. The UK Chemotherapy Board recognised the many current examples of good practice but noted an inconsistency of approach between centres which may limit sharing of learning. It has summarised the key details of the processes currently used and developed a proposed template for an operational policy and pro forma.